You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
麗珠醫藥(01513.HK)獲上市委員會同意分拆麗珠試劑於新三板上市
阿思達克 12-11 08:56
麗珠醫藥(01513.HK)公布,已獲香港聯交所上市委員會同意,分拆麗珠試劑及於全國中小企業股份轉讓系統掛牌。 建議分拆麗珠試劑至新三板將不會發行任何新股份,該公司於麗珠試劑的股權維持47.43%不變。視乎市況及所需監管批准,麗珠試劑可能轉至北京證券交易所發售新A股,建議股份發售若落實,將導致該公司在麗珠試劑的股權稀釋。 根據相關中國法律的相關規定,建議分拆至新三板及建議中國上市,尚需提交公司股東大會批准。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account